title: Expression of adrenomedullin 2/intermedin in human adrenal tumors and attached non-neoplastic adrenal tissues.
abstract: Adrenomedullin 2/intermedin (AM2/IMD) is a new member of calcitonin/calcitonin gene-related peptide family. AM is expressed in various tumors including adrenocortical tumors and modulates tumor growth. The AM2/IMD expression has not been studied, however, in adrenal tumors. The expression of AM2/IMD and AM was therefore studied in human adrenal tumors and attached non-neoplastic adrenal tissues by immunocytochemistry (ICC). Immunoreactive (IR)-AM2/IMD was measured by RIA. Furthermore, the expression of AM2/IMD and its receptor components, calcitonin receptor-like receptor (CRLR), and receptor activity-modifying proteins (RAMPs) 1, 2, and 3 mRNA in these tissues was studied by reverse transcription PCR (RT-PCR). ICC showed that AM2/IMD and AM immunoreactivities were localized in adrenocortical tumors and pheochromocytomas. AM2/IMD and AM immunoreactivities were detected in medulla of attached non-neoplastic tissues, while the degree of immunoreactivity for AM2/IMD and AM in cortices of attached adrenals was relatively weak or undetectable. RIA detected IR-AM2/IMD in adrenal tumors (0.414+/-0.12 to 0.786+/-0.27 pmol/g wet weight, mean+/-S.E.M.) and attached adrenal tissues (0.397+/-0.052 pmol/g wet weight). Reverse-phase high-performance liquid chromatography showed one broad peak eluted in the similar position to synthetic AM2/IMD with several minor peaks. RT-PCR showed expression of AM2/IMD, CRLR, and RAMP1, RAMP2, and RAMP3 mRNA in tissues of adrenal tumors and attached adrenal glands. In conclusion, AM2/IMD is expressed in human adrenal tumors and attached non-neoplastic adrenal tissues and may play (patho-)physiological roles in normal and neoplastic adrenals as an autocrine/paracrine regulator.
authors.affiliation: Division of Nephrology, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Morimoto
authors.forename: Fumitoshi
authors.initials: F
authors.lastname: Satoh
authors.forename: Osamu
authors.initials: O
authors.lastname: Murakami
authors.forename: Takuo
authors.initials: T
authors.lastname: Hirose
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Totsune
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Imai
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Arai
authors.forename: Takashi
authors.initials: T
authors.lastname: Suzuki
authors.forename: Hironobu
authors.initials: H
authors.lastname: Sasano
authors.forename: Sadayoshi
authors.initials: S
authors.lastname: Ito
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takahashi
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000737:chemistry*; D000311:Adrenal Glands / Q000737:chemistry*; D018268:Adrenocortical Carcinoma / Q000737:chemistry; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D036361:Peptide Hormones / Q000032:analysis* / Q000235:genetics / Q000502:physiology; D010673:Pheochromocytoma / Q000737:chemistry; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: C484330:ADM2 protein, human; D036361:Peptide Hormones; D012333:RNA, Messenger